Latest News Archive

Please select Category, Year, and then Month to display items

Tackling gender inequality and discrimination

31 July 2023 | Story Valentino Ndaba

The Gender Equality and Anti-Discrimination Office (GEADO) is an integral part of the University of the Free State’s (UFS) Unit for Institutional Change and Social Justice. Its primary focus is to create a safe and inclusive environment for students and staff. The office plays a crucial role in shaping the student experience and in fostering inclusivity in student accommodation and residence environments.

The GEADO takes proactive steps to achieve this, including implementing guidelines and policies to address and prevent gender-based violence and sexual misconduct. It also conducts conscientisation workshops to raise awareness, challenge biases, and promote empathy among stakeholders.

“As an integral component of our initiatives, the GEADO implements proactive measures to foster safe spaces for students, through the establishment of its Sexual Offence Response Team (SORT) and sexual harassment guidelines,” said Dr Lentsu Nchabeleng, Deputy Director of the Gender Equality and Anti-Discrimination Office. She further emphasised, “These frameworks are formulated to tackle and prevent occurrences of gender-based violence and sexual misconduct, ensuring a secure, healthy, and conducive environment for both students and staff to flourish and develop as individuals and as a community.” The GEADO is currently reviewing the UFS Sexual Harassment, Sexual Misconduct, and Sexual Violence Policy to strengthen its commitment to a zero-tolerance stance on gender-based violence and sexual misconduct.

Beyond addressing specific incidents, the GEADO aims to cultivate an inclusive and socially just atmosphere across the UFS’s campuses. It closely monitors the environment, identifies trends, and stays updated on global and local interventions to positively impact its work.

The office is a driving force behind fostering a safe, inclusive, and socially just campus culture that embraces gender equality and combats discrimination. It partners with LGBTIAQ+ (lesbian, gay, bisexual, transgender, intersex, asexual, queer, and others) organisations like Free State Rainbow Seeds to further support its mission. Some of the programmes championed by the office include safety zone training, sexuality sensitisation, and diversity training.

Safe zone training

The Safe Zones@UFS project is modelled after a similar programme in the USA, specifically the Safe Zones Project at San Diego State University. Its purpose is to create a supportive and safe environment for individuals who identify as LGBTIAQ+.

Dr Nchabeleng said the project encompasses the training of faculty members and students to become Safe Zones allies, offering support to students, staff, as well as families and friends of individuals identifying as LGBTIAQ+. She emphasised that the role of Safe Zone allies involves providing assistance to LGBTIAQ+ students and staff during their coming-out process, serving as an informative resource for LGBTIAQ+ matters, advocating for LGBTIAQ+ rights, and acting as a referral point for other essential services, including medical and counselling support.

Sexuality sensitisation

Gender and sexuality sensitisation is crucial for fostering inclusive and respectful environments in educational institutions, workplaces, and communities. It involves raising awareness about consent, sexual minorities, and diverse gender identities, while addressing gender-based violence, sexual harassment, and misconduct. The approach includes consent education, understanding sexual minorities, exploring gender identities, combating gender-based violence and harassment, promoting safe spaces, challenging stereotypes, encouraging allyship, and promoting positive masculinity and femininity. Overall, these efforts create a more understanding and supportive community in which individuals of all genders and sexual orientations can thrive.

Diversity Training

The Diversity Training programme focuses on increasing awareness and understanding of diverse backgrounds and experiences. It includes workshops and training to address unconscious bias, promoting a fair and equitable environment. The goal is to create a sense of belonging, where everyone feels accepted and valued. The programme is flexible and can be customised for organisations or communities, and it can be delivered through various formats. Embracing diversity and inclusion can lead to better outcomes, improved teamwork, and the attracting of diverse talent. Overall, it fosters a culture of inclusivity and appreciation for diverse perspectives, benefitting both individuals and organisations.

Important contact information

Bloemfontein Campus: +27 51 401 3982

South Campus: +27 51 401 7544

Qwaqwa Campus: +27 58 718 5431

Toll-free number +27 80 020 4682

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept